Floatz logo

Cytosin-Arabinosid

Chemotherapeutic Agent Toxicity

Instituto do Cancer do Estado de São PauloPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

65 Active assets in the Chemotherapeutic Agent Toxicity cohort.

Asset / SponsorPhaseRating
Palonosetron
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4A
DEXAMETHASONE
Instituto do Cancer do Estado de São Paulo
Phase 4A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BB
HR20013
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →